Lyzorca

Pregabalin

Peripheral & central neuropathic pain, generalised anxiety disorder (GAD) in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisation. Management of fibromyalgia.

Neuropathic pain Initially 150 mg daily in 2 or 3 divided doses, may be increased to 300 mg daily after 3-7 days interval. Max: 600 mg daily after additional 7-day interval. GAD 150-600 mg daily in 2 or 3 divided doses. Initially 150 mg daily, may be increased to 300 mg daily after 1 wk, then to 450 mg daily following additional wk. Max: 600 mg daily after additional wk. Epilepsy Initially 150 mg daily, may be increased to 300 mg daily after 1 wk. Max: 600 mg daily after additional wk. Fibromyalgia 300-450 mg daily in 2 divided doses. Start at 75 mg bd, may be increased to 150 mg bd w/in 1 wk or may be further increased to 225 mg bd. Max: 600 mg daily after additional wk. CrCl ≥60 mL/min Initially 150 mg daily in 2 or 3 divided doses. Max: 600 mg daily, ≥30 to <60 mL/min Initially 75 mg daily in 2 or 3 divided doses. Max: 300 mg daily, ≥15 to <30 mL/min Initially 25-50 mg once daily or in 2 divided doses. Max: 150 mg daily, <15 mL/min Initially 25 mg once daily. Max: 75 mg daily. Supplementary dose following haemodialysis Initially 25 mg daily as single dose given immediately following every 4-hr haemodialysis. Max: 100 mg daily.

May be taken with or without food.

Hypersensitivity.

Discontinue use if hypersensitivity; life-threatening angioedema; diagnosed or suspected myopathy elevated creatine kinase levels occur. Increased risk of suicidal thoughts or behavior. Peripheral edema; CHF patients w/ NYHA class III or IV; dizziness & somnolence; loss of consciousness, confusion & mental impairment; wt gain; prolonged PR interval; decreased platelet counts; encephalopathy; tumorigenic potential; ophthalmological effects. Monitor symptoms of resp depression & sedation in co-administration w/ CNS depressants including opioids or in setting of underlying resp impairment. Evaluate patients for history of drug abuse & symptoms of misuse or abuse or dependence eg, development of tolerance, dose escalation, drug-seeking behavior. Avoid abrupt or rapid discontinuation; taper-off gradually over at least 1 wk. Concomitant use w/ anti-spasticity agents. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Renal failure. Women of childbearing potential must use effective contraception. Not to be used during pregnancy. Lactation. Not recommended in childn <12 yr & adolescents. Elderly >65 yr.

Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, attention disturbance, paraesthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back & limb pain, cervical spasm; peripheral oedema, oedema, abnormal gait, fall, feeling drunk & abnormal, fatigue; increased wt.

Potentiated ethanol & lorazepam effects. Additive impairment of cognitive & gross motor function w/ oxycodone. Resp failure & coma w/ other CNS depressants. Reduced lower GI tract function w/ opioid analgesics.

Anticonvulsants / Drugs for Neuropathic Pain

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

B